Buy Cipla; target of Rs 1600: Motilal Oswal
Motilal Oswal is bullish on Cipla recommended buy rating on the stock with a target price of Rs 1600 in its research report dated January 25, 2024.29-01-2024
29-01-2024
CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
We are enclosing herewith copy of the transcript of the Company''s Q3FY24 earnings conference call dated 25th January 2024.29-01-2024
Samina Hamied steps down as Cipla executive vice chairperson. Details here
Samina Hamied steps down as Executive Vice Chairperson of the company, but will continue as a non-executive director.27-01-2024
Cipla's Samina Hamied steps down citing personal commitments
Samina is the niece of Cipla non-executive chairman YK Hamied, and daughter of his brother and non-executive vice-chairman, MK Hamied. The company said she would continue as a non-executive director.26-01-2024
CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30(6) read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, the audio recording of the earnings conference call for Q3 FY 24.25-01-2024
CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Change in Directorate
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as enclosed.25-01-2024
Cipla sets up subsidiary in Mexico
Mexicip is incorporated with an objective of sale and distribution of pharmaceutical drugs23-01-2024
Q3FY24 Quarterly Result Announced for Cipla Ltd.
Pharmaceuticals firm Cipla announced Q3FY24 result: Financial Highlights: Income from Operations: Rs 6,544 crore, representing a 14.2% YoY increase. EBITDA: Rs 1,720 crore, translating to 26.3% of Income from Operations, reflecting a 24.9% YoY growth. Profit After Tax (PAT): Rs 1,049 crore, marking a substantial increase of 32.7% YoY. Business Performance by Region: One-India: Revenue growth stood at 12% YoY, bolstered by Branded Prescription, Trade Generics, and Consumer Health verticals. The market share for chronic therapy increased by 115 bps YoY to 60.3%. North America: Recorded highest ever quarterly revenue at $230 Mn, an 18% YoY growth, driven by volume traction in key assets such as Lanreotide and Albuterol, along with strong base business demand. South Africa: Demonstrated a 15% growth in local currency terms YoY, fueled by strong performance across prescription, OTC, and tender segments. Research and Development (R&D;): Investment: R&D; investments were reported at Rs 400 crore or 6.1% of sales, showcasing an increase of 10% YoY. Balance Sheet Health: Robust Net Cash Position: Rs 7,143 crore post the repayment of ZAR 720 Mn term loan in South Africa. Umang Vohra, MD and Global CEO of Cipla Ltd, stated: "I am happy to announce results for yet another quarter which further established our strengths of our core business in India, North America, and South Africa. Our topline growth for the quarter was at an impressive 14% YoY with strong EBITDA margins at 26.3%. One India business grew at a healthy 12% YoY backed by strong performance across Branded Prescroreiption, Trade Generics and Consumer Health. In North America, we continue to scale newer peaks by posting the highest ever quarterly revenue yet again at $ 230 Mn, supported by positive traction in key assets and base business. Our South Africa business further extended its momentum from last quarter by growing at 15% in local currency terms driven by strong execution across prescription, OTC, and tender. Our focus continues on expansion in chronic therapies, growing big brands, global wellness as well as developing our R&D; pipeline in respiratory and peptides. We will continue to focus on driving profitable growth across businesses". Result PDF23-01-2024
CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Acquisition
Cipla (EU) Limited, UK and Cipla Holding BV, Netherlands, wholly owned subsidiaries of the Company have jointly incorporated ''Mexicip S.A.de C.V.'', a wholly owned subsidiary in Mexico w.e.f. 22 January 2024.23-01-2024
CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Investor Presentation
Please find the enclosed investor presentation for Q3FY24 unaudited financial result.22-01-2024